Sarah Sammons, Co-Leader of Breast Oncology at UMGCCC and former Senior Physician at Dana-Farber, shared Paolo Tarantino’s, Research Fellow Dana-Farber Cancer Institute and Harvard Medical Schoolpost, post on X, adding:
“Tucatinib and TDXd are the two most effective drugs for patients facing HER2+ breast cancer brain metastases. Adding them together led to a PFS of 20 months for BM patients.
For now best to use these agents sequentially and not together.”
Quoting Paolo Tarantino’s post:
“Results from HER2CLIMB-04 show that combining T-DXd with tucatinib does not lead to higher efficacy than T-DXd monotherapy. Follows the disappointing results of HER2CLIMB-02 (T-DM1 + tuc). Tucatinib stabilizes HER2 on the membrane: bad partner for ADCs?”
Title: Tucatinib in Combination With Trastuzumab Deruxtecan in Patients With Previously Treated HER2+ Unresectable Locally Advanced or Metastatic Breast Cancer: An Open-Label Phase 2 Study
Authors: Shanu Modi, Rashmi K. Murthy, A. Jo Chien, Nancy U. Lin, Nicholas P. McAndrew, Jennifer M. Specht, Amelia B. Zelnak, Jorge Ramos, Diqiong Xie, Joel Ho, Juliet K. Inoue, Lisa A. Carey, Erika P. Hamilton
Other articles featuring Sarah Sammons and Paolo Tarantino on OncoDaily.